Search

Your search keyword '"Cenderello, G."' showing total 278 results

Search Constraints

Start Over You searched for: Author "Cenderello, G." Remove constraint Author: "Cenderello, G."
278 results on '"Cenderello, G."'

Search Results

1. People with HIV pioneers of injectable cabotegravir and rilpivirine long acting in Italy: who are they?

2. TD-1 Efficacy, safety and metabolic changes at 6-months after switch to long-acting injectable CAB/RPV: results from an observational prospective multicenter study

3. Low level viremia at the beginning and in course of long-acting treatment with injectable cabotegravir and rilpivirine

4. Lipids, weight gain and body mass index in ARV experienced PLWH treated with doravirine-based treatments: a comparison between dual or triple regimens vs bictegravir based triple regimen

5. Risk of Cardiovascular Events in People with HIV (PWH) Treated with Integrase Strand-Transfer Inhibitors: The Debate Is Not Over; Results of the SCOLTA Study

6. Epidemiology, aetiology and treatment of skin and soft tissue infections: final report of a prospective multicentre national registry

7. Cost per care of the first year of direct antiviral agents in the Liguria Region: a multicenter analysis

8. Lipids and Transaminase in Antiretroviral-Treatment-Experienced People Living with HIV, Switching to a Doravirine-Based vs. a Rilpivirine-Based Regimen: Data from a Real-Life Setting

9. Real-life safety of Emtricitabine/Tenofovir Alafenamide/Bictegravir

10. Prevalence of HDV infection in people living with HIV: Data from a multicenter Italian cohort

11. Causes of HIV Treatment Interruption during the Last 20 Years: A Multi-Cohort Real-Life Study

12. Metabolic syndrome and body weight in people living with HIV infection: analysis of differences observed in three different cohort studies over a decade

14. Off-label use of combined antiretroviral therapy, analysis of data collected by the Italian Register for HIV-1 infection in paediatrics in a large cohort of children

15. Budget impact analysis of sofosbuvir-based regimens for the treatment of HIV/HCV-coinfected patients in northern Italy: a multicenter regional simulation

16. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

17. Resistance analysis and treatment outcomes in hepatitis C virus genotype 3-infected patients within the Italian network VIRONET-C

18. Cost of HAART in Italy: multicentric evaluation and determinants from a large HIV outpatient cohort

19. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

20. Burden of Disease in PWH Harboring a Multidrug-Resistant Virus: Data from the PRESTIGIO Registry

21. Growing old with antiretroviral therapy or elderly people in antiretroviral therapy: two different profiles of comorbidity?

22. Invecchiare con la terapia antiretrovirale o essere anziani in terapia antiretrovirale: due profili di comorbidità differenti?

23. Intravenous methylprednisolone pulses in hospitalised patients with severe COVID-19 pneumonia, A double-blind, randomised, placebo-controlled trial

24. The multidimensional prognostic index (MPI) for the prognostic stratification of older inpatients with COVID-19: A multicenter prospective observational cohort study

25. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: Results from a large multicentre observational prospective cohort (SCOLTA)

26. Positioning of darunavir/cobicistat-containing antiretroviral regimens in real life: results from a large multicentre observational prospective cohort (SCOLTA)

27. Factors associated with hospital admission for COVID-19 in HIV patients

30. Correction to: Tocilizumab for patients with COVID-19 pneumonia. The single-arm TOCIVID-19 prospective trial (Journal of Translational Medicine, (2020), 18, 1, (405), 10.1186/s12967-020-02573-9)

31. Fattori associati con il ricovero ospedaliero per COVID-19 in 80 pazienti HIV-positivi italiani. Factors associated with hospital admission for COVID-19 in 80 Italian HIV patients.

32. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study

33. Prevalence of acquired resistance mutations in a large cohort of perinatally infected HIV-1 patients

34. Weight gain in dolutegravir containing regimens in the observational SCOLTA cohort

36. Factors Associated With Weight Gain in People Treated With Dolutegravir

37. Factors associated with hospital admission for COVID-19 in HIV patients

38. VIRONET-C real life experience of resistance-guided retreatment in HCV infected patients who previously failed a NS5A inhibitor-containing regimen

39. Effect of hepatitis B virus on steatosis in hepatitis C virus co-infected subjects: A multi-centre study and systematic review

40. Long-term efficacy of dolutegravir in treatment-experienced subjects failing therapy with HIV-1 integrase strand inhibitor-resistant virus

42. Predictors of severe weight gain in patients treated with Dolutegravir

43. Epidemiology and Microbiology of Skin and Soft Tissue Infections: Preliminary Results of a National Registry

45. Dolutegravir safety in a real-life setting: results from the SCOLTA cohort

46. DECLINE OF PREVALENCE OF RESISTANCE ASSOCIATED SUBSTITUTIONS TO NS3 AND NS5A INHIBITORS AT DAA- FAILURE IN HEPATITIS C VIRUS IN ITALY OVER THE YEARS 2015 TO 2018

47. Resistance test guided retreatment of HCV infected patients with a previous failure to a NS5A inhibitor-containing regimen: the Italian Vironet C real life experience

Catalog

Books, media, physical & digital resources